BET Inhibitors Sensitize Cancer Cells to PARP Inhibitors

Technology #2015-196

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Zhenkun Lou Ph.D.
Min Deng Ph.D.
Managed By
Leif R. Nelson
Patent Protection
US Patent Pending

Mayo Clinic has discovered that BET inhibitors hinder the homologous recombination process in DNA repair and that BET inhibitors sensitize tumors to PARP inhibitor treatment.